Our previous studies demonstrated that hepatitis C virus (HCV) envelope glycoproteins, E1 and E2, display distinct reactivity to different cell surface molecules. In this study, we characterized the interaction of E1 and E2 with apolipoproteins in facilitating virus entry. The results suggested a higher neutralization of VSV/HCV E1-G pseudotype infectivity by antibodies to apolipoprotein E (ApoE) than apolipoprotein B (ApoB), with VSV/HCV E2-G pseudotype infectivity remaining largely unaffected. Neutralization of cell culture grown HCV infectivity by antiserum to ApoE, and to a lesser extent by ApoB, further verified their involvement in virus entry. HCV E1, but not E2, displayed binding with ApoE and ApoB by ELISA. Binding of E1 with apolipoproteins were further supported by coimmunoprecipitation from human hepatocytes expressing E1. Rabbit antiserum to a selected E1 ectodomain derived peptide displayed ~50% neutralization of E1-G pseudotype infectivity. Furthermore, E1 ectodomain derived synthetic peptides significantly inhibited the interaction of E1 with both the apolipoproteins. Investigation on the role of LDL-R as a hepatocyte surface receptor for virus entry suggested a significant reduction in E1-G pseudotype plaque numbers (~70%) by inhibiting LDL-R ligand binding activity using human proprotein convertase subtilisin/kexin type 9 (PCSK9) and platelet factor-4 (PF4), while they had a minimal inhibitory effect on E2-G pseudotype.
Conclusion
Together, the results suggested an association between HCV E1 and apolipoproteins, which may facilitate virus entry through LDL-R into mammalian cells.